Centrient Pharmaceuticals
Centrient Pharmaceuticals, a leading name in pharmaceutical preparation manufacturing, is headquartered in the Netherlands and operates across key regions in Europe, Asia, and North America. Founded in 2017, the company has quickly established itself as a significant player in the industry, focusing on the development and production of essential antibiotics and anti-infectives.
Centrient's core offerings include a range of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms, distinguished by their commitment to sustainability and innovation. The company is recognised for its advanced manufacturing processes and dedication to meeting global health needs, positioning itself as a trusted partner in the pharmaceutical supply chain. With a strong emphasis on quality and compliance, Centrient Pharmaceuticals continues to achieve notable milestones, reinforcing its market position as a reliable provider of critical healthcare solutions.
+33 vs industry average
Centrient Pharmaceuticals’s score of 71 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Centrient Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Centrient Pharmaceuticals's reported carbon emissions
Centrient Pharmaceuticals, a Pharmaceutical Preparation Manufacturing company headquartered in the Netherlands, is actively working to reduce its carbon footprint.
In 2025, Centrient Pharmaceuticals reported a total of approximately 601.8 million kg CO2e. This figure is comprised of Scope 1 emissions totalling around 101.5 million kg CO2e, Scope 2 emissions (market-based) of approximately 148.0 million kg CO2e, and Scope 3 emissions amounting to about 352.3 million kg CO2e. Within Scope 3, purchased goods and services represent the largest category, accounting for approximately 244.4 million kg CO2e.
The company's emissions data for 2024 showed a total of approximately 697.0 million kg CO2e, with Scope 1 emissions at around 142.9 million kg CO2e, Scope 2 (market-based) at approximately 118.1 million kg CO2e, and Scope 3 at about 436.1 million kg CO2e. Purchased goods and services were also the largest Scope 3 contributor in 2024, at approximately 289.7 million kg CO2e.
For 2023, Centrient Pharmaceuticals reported total emissions of approximately 733.0 million kg CO2e. This included Scope 1 emissions of about 143.3 million kg CO2e, Scope 2 (market-based) of approximately 141.4 million kg CO2e, and Scope 3 emissions of roughly 448.2 million kg CO2e. Purchased goods and services were the primary driver of Scope 3 emissions, at approximately 322.2 million kg CO2e.
In 2022, the company's total emissions were approximately 641.3 million kg CO2e. This was broken down into Scope 1 emissions of around 136.7 million kg CO2e, Scope 2 (market-based) of approximately 145.7 million kg CO2e, and Scope 3 emissions totalling about 358.8 million kg CO2e.
Centrient Pharmaceuticals has established several significant climate commitments. Notably, the company has committed to an absolute reduction in Scope 1 and 2 GHG emissions of 46.2% by 2031, using 2022 as the base year. Furthermore, they have committed to reducing absolute Scope 3 GHG emissions from purchased goods and services and fuel and energy-related activities by 27.5% within the same timeframe. These targets align with keeping global warming to 1.5°C and have been set in alignment with Science Based Targets initiative (SBTi) standards.
Additional reduction initiatives include aiming for a 35% reduction in carbon emission intensity by 2025 and 50% by 2030, using 2015 as a baseline year. The company also reported a 7.5% reduction in intensity (tCO2e/T produced) in 2023.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Centrient Pharmaceuticals’s Climate Goals (2030 & 2050)
3 goals2025
35% reduction in all scopes
35% reduction in carbon emission intensity (2025) and 50% by 2030*
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 3 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Centrient Pharmaceuticals
Frequently asked questions
Common questions about Centrient Pharmaceuticals’s sustainability data and climate commitments
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project